A clinical trial of bromocriptine for treatment of primary progressive aphasia
โ Scribed by Deborah A. Reed; Nancy A. Johnson; Cynthia Thompson; Sandra Weintraub; M.-Marsel Mesulam
- Publisher
- John Wiley and Sons
- Year
- 2004
- Tongue
- English
- Weight
- 116 KB
- Volume
- 56
- Category
- Article
- ISSN
- 0364-5134
No coin nor oath required. For personal study only.
โฆ Synopsis
Due to an editing error, the final sentence in the published abstract was reproduced incorrectly. The correct sentence is "The role of the pedunculopontine and cuneiform nuclei, and related brainstem structures, in mediating motor activity and controlling muscle tone suggests that alterations in these structures could underlie the pathophysiology of DYT1 dystonia."
The publishers regret this oversight.
๐ SIMILAR VOLUMES
Seven patients with vascular dementia completed an 8month randomized double-blind crossover trial of bromocriptine i n a dosage of u p to 30 mg per day. Patients were assessed using a modified UCLA Parkinson Rating Scale of symptoms and signs, and neuropsychological testing including the Wechsler Ad
When a clinical trial is conducted at more than one centre it is likely that the true treatment effect will not be identical at each centre. In other words there will be some degree of treatment-by-centre interaction. A number of alternative approaches for dealing with this have been suggested in th
Abstract One hundred and thirty-seven consecutive acute superficial abscesses were randomly allocated to incision, curettage and primary suture without parenteral antibiotics (64 cases) or to conventional treatment with incision, drainage and dressings (73 cases). Wound healing was faster; 7.0 days: